albuterol / budesonide vs Fluticasone Furoate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Reported efficacy
Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)
Result source: NCT05505734
Fluticasone Furoate · Arnuity Ellipta
Marketed by GlaxoSmithKline
NCT00603382 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial with about 95 to 110 people per group. Its primary lung-function comparison (trough FEV1) was significant for the 50, 100 and 200 microgram doses but not for the lowest 25 microgram dose, so the primary result is mixed across the doses tested.
Reported efficacy
Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) (met)
Result source: NCT00603278
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol / budesonide | Fluticasone Furoate |
|---|---|---|
| Severe exacerbations, annualised rate | 0.5 vs 0.6vs AS MDINCT037690902 other results
| —Trial running · NCT04651777 |
| Trough FEV1, change | 0.1 vs 0.0+0.1 vs placeboNCT038478963 other results
| 0.4 vs 0.2+0.2 vs placeboNCT0116513819 other results
|
| ACQ-5, change | —Not posted · NCT06502366 | —Trial running · NCT04651777 |
| OCS dose reduction | —Not posted · NCT06502366 | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- albuterol / budesonide
- 0.5 vs 0.6vs AS MDINCT03769090
2 other results
- 0.1 vs 0.3 NCT05505734
- 0.1 vs 0.3 NCT05505734
- Fluticasone Furoate
- —Trial running · NCT04651777
Trough FEV1, change
- albuterol / budesonide
- 0.1 vs 0.0+0.1 vs placeboNCT03847896
3 other results
- 0.1 vs 0.0 NCT03847896
- 0.1 vs 0.0 NCT03847896
- 0.1 vs 0.0 NCT03847896
- Fluticasone Furoate
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
19 other results
- 0.2 vs 0.0 NCT01159912
- 0.2 vs 0.0 NCT01436071
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- -0.1 vs -0.1 NCT02094937
- 0.2 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.1 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.1 NCT00603278
- 0.2 vs 0.1 NCT01563029
- -0.5 vs -0.8 NCT01128569
- 0.1 vs 0.1 NCT01563029
- 0.3 vs 0.1 NCT01563029
ACQ-5, change
- albuterol / budesonide
- —Not posted · NCT06502366
- Fluticasone Furoate
- —Trial running · NCT04651777
OCS dose reduction
- albuterol / budesonide
- —Not posted · NCT06502366
- Fluticasone Furoate
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. albuterol / budesonide: 4 of 4 rows · Fluticasone Furoate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | albuterol / budesonide | Fluticasone Furoate |
|---|---|---|
| Dropout rate | 9.9%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results11.7%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 28.2%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 3.6%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 7.8%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 —160/180 NCT06245551 · Phase 3 — NCT05555290 · Phase 3 · registry result, not featured evidence — NCT04234464 · Phase 3 · registry result, not featured evidence —160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence | 9.5%200 µg ODb NCT00603382 · Phase 2 show 41 more results10.9%100 µg OD NCT00603382 · Phase 2 9%50 µg OD NCT00603382 · Phase 2 14.4%25 µg OD NCT00603382 · Phase 2 13.9%200 µg OD NCT00603278 · Phase 2 16.2%100 µg OD NCT00603278 · Phase 2 13.1%400 µg OD NCT00603278 · Phase 2 10.7%300 µg OD NCT00603278 · Phase 2 18.2%200 µg OD NCT00603746 · Phase 2 16.7%800 µg OD NCT00603746 · Phase 2 12.1%600 µg OD NCT00603746 · Phase 2 7.9%400 µg OD NCT00603746 · Phase 2 19.3%100 µg OD NCT01159912 · Phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 12.6%200 µg OD NCT01431950 · Phase 3 16%100 µg OD NCT01431950 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 28%100 µg OD NCT01563029 · Phase 2 27.5%50 µg OD NCT01563029 · Phase 2 20.3%25 µg OD NCT01563029 · Phase 2 13.9%50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy — NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 7.2%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 9.2%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 22.2%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 11.3%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence —100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence —200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence —100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 1.8%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 3.6%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence —100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —100 µg NCT01332292 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence —200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence —100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.7%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results0.7%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 0.5%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 1%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 0.5%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 —160/180 NCT06245551 · Phase 3 — NCT05555290 · Phase 3 · registry result, not featured evidence — NCT04234464 · Phase 3 · registry result, not featured evidence —160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence | 1.1%200 µg ODb NCT00603382 · Phase 2 show 41 more results1.8%100 µg OD NCT00603382 · Phase 2 1%50 µg OD NCT00603382 · Phase 2 1%25 µg OD NCT00603382 · Phase 2 1%200 µg OD NCT00603278 · Phase 2 2.9%100 µg OD NCT00603278 · Phase 2 2%400 µg OD NCT00603278 · Phase 2 0%300 µg OD NCT00603278 · Phase 2 3%200 µg OD NCT00603746 · Phase 2 0%800 µg OD NCT00603746 · Phase 2 0.9%600 µg OD NCT00603746 · Phase 2 0%400 µg OD NCT00603746 · Phase 2 1.8%100 µg OD NCT01159912 · Phase 3 1%100/25 µg OD NCT01165138 · Phase 3 1.7%200 µg OD NCT01431950 · Phase 3 1.7%100 µg OD NCT01431950 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1.7%100 µg OD NCT01563029 · Phase 2 0.8%50 µg OD NCT01563029 · Phase 2 0%25 µg OD NCT01563029 · Phase 2 —50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy — NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 0.9%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0.9%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0.9%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 0%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence —100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence —200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence —100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 0%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence —100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —100 µg NCT01332292 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence —200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence —100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.2%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results3.8%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 3.1%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 1%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 2%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 0%160/180 NCT06245551 · Phase 3 0% NCT05555290 · Phase 3 · registry result, not featured evidence 0% NCT04234464 · Phase 3 · registry result, not featured evidence 0%160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence | 0%200 µg ODb NCT00603382 · Phase 2 show 41 more results0.9%100 µg OD NCT00603382 · Phase 2 0%50 µg OD NCT00603382 · Phase 2 1%25 µg OD NCT00603382 · Phase 2 0%200 µg OD NCT00603278 · Phase 2 0%100 µg OD NCT00603278 · Phase 2 1%400 µg OD NCT00603278 · Phase 2 1%300 µg OD NCT00603278 · Phase 2 2%200 µg OD NCT00603746 · Phase 2 0%800 µg OD NCT00603746 · Phase 2 0.9%600 µg OD NCT00603746 · Phase 2 0%400 µg OD NCT00603746 · Phase 2 3.5%100 µg OD NCT01159912 · Phase 3 0%100/25 µg OD NCT01165138 · Phase 3 3.4%200 µg OD NCT01431950 · Phase 3 2.5%100 µg OD NCT01431950 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 0.8%100 µg OD NCT01563029 · Phase 2 0.8%50 µg OD NCT01563029 · Phase 2 0%25 µg OD NCT01563029 · Phase 2 2.5%50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy 0% NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 0.3%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 1.2%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 0.8%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence 4.1%100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence 0.5%200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 1.5%100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 0%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence 0%100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%100 µg NCT01332292 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence 0%200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence 0%100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 8 more results160/180 μg upper respiratory tract infection 5.4% covid-19 5.1% nasopharyngitis 3.7% NCT05505734 · Phase 3 · Asthma · phase 3 160/180 μg nasopharyngitis 7.6% (placebo 5.5%) headache 5.1% (placebo 7%) dysphonia 2% (placebo 0%) NCT03847896 · Phase 3 · Asthma · phase 3 80/180 μg nasopharyngitis 6.4% (placebo 5.5%) headache 4.9% (placebo 7%) upper respiratory tract infection 1.5% (placebo 1%) NCT03847896 · Phase 3 · Asthma · phase 3 160/180 bronchial irritation 1.6% (placebo 0%) diarrhoea 0% (placebo 1.6%) headache 0% (placebo 1.6%) NCT06245551 · Phase 3 anxiety 0% (placebo 1.7%) dyspnoea 0% (placebo 1.7%) NCT04234464 · Phase 3 · registry result, not featured evidence | 200 µg ODb headache 5.3% (placebo 10.6%) nasopharyngitis 3.2% (placebo 1.1%) oropharyngitis 3.2% (placebo 1.1%) NCT00603382 · Phase 2 show 40 more results100 µg OD headache 10.9% (placebo 10.6%) nasopharyngitis 3.6% (placebo 1.1%) oropharyngitis 3.6% (placebo 1.1%) NCT00603382 · Phase 2 50 µg OD headache 6% (placebo 10.6%) back pain 3% (placebo 0%) oropharyngitis 1% (placebo 1.1%) NCT00603382 · Phase 2 25 µg OD headache 6.2% (placebo 10.6%) back pain 0% (placebo 0%) nasopharyngitis 0% (placebo 1.1%) NCT00603382 · Phase 2 200 µg OD headache 7.9% (placebo 5.6%) nasopharyngitis 5% (placebo 7.5%) upper respiratory tract infection 3% (placebo 2.8%) NCT00603278 · Phase 2 100 µg OD headache 8.6% (placebo 5.6%) nasopharyngitis 8.6% (placebo 7.5%) diarrhoea 3.8% (placebo 0%) NCT00603278 · Phase 2 400 µg OD headache 9.1% (placebo 5.6%) cough 4% (placebo 0.9%) nasopharyngitis 4% (placebo 7.5%) NCT00603278 · Phase 2 300 µg OD headache 7.8% (placebo 5.6%) nasopharyngitis 6.8% (placebo 7.5%) back pain 2.9% (placebo 0%) NCT00603278 · Phase 2 200 µg OD dysphonia 4% (placebo 1%) oropharyngeal candidiasis 4% (placebo 1%) headache 3% (placebo 9.7%) NCT00603746 · Phase 2 800 µg OD headache 9.8% (placebo 9.7%) nasopharyngitis 6.9% (placebo 3.9%) oral candidiasis 6.9% (placebo 0%) NCT00603746 · Phase 2 600 µg OD headache 11.2% (placebo 9.7%) back pain 3.7% (placebo 1%) pharyngolaryngeal pain 2.8% (placebo 1%) NCT00603746 · Phase 2 400 µg OD headache 9.9% (placebo 9.7%) dysphonia 5% (placebo 1%) nasopharyngitis 5% (placebo 3.9%) NCT00603746 · Phase 2 100 µg OD nasopharyngitis 7.9% (placebo 5.2%) bronchitis 7% (placebo 6.1%) headache 6.1% (placebo 4.3%) NCT01159912 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100 µg OD cough 8.5% (placebo 5%) headache 5.9% (placebo 1.7%) rhinorrhoea 5.1% (placebo 1.7%) NCT01563029 · Phase 2 50 µg OD pharyngitis 5.8% (placebo 3.4%) bronchitis 3.3% (placebo 0.8%) nasopharyngitis 3.3% (placebo 3.4%) NCT01563029 · Phase 2 25 µg OD nasopharyngitis 7.6% (placebo 3.4%) cough 5.9% (placebo 5%) oropharyngeal pain 5.1% (placebo 0.8%) NCT01563029 · Phase 2 50 mcg upper respiratory tract infection 12.2% (placebo 13.8%) nasopharyngitis 9.7% (placebo 10.5%) rhinitis 6.7% (placebo 7.5%) NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy nasopharyngitis 6.9% (placebo 8.3%) headache 5.2% (placebo 13.3%) cough 3.4% (placebo 5%) NCT02502734 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 · registry result, not featured evidence 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 · registry result, not featured evidence 50 µg OD headache 14.5% (placebo 11.3%) nasopharyngitis 6.8% (placebo 5.2%) pharyngitis 6% (placebo 8.7%) NCT01436110 · Phase 3 · registry result, not featured evidence 50 µg OD nasopharyngitis 5.8% (placebo 4.1%) headache 5% (placebo 11.6%) pharyngitis 5% (placebo 5%) NCT01436071 · Phase 3 · registry result, not featured evidence 100/25 µg headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 · registry result, not featured evidence 200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 · registry result, not featured evidence 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 · registry result, not featured evidence 200/25 µg PM headache 16.1% (placebo 8.6%) back pain 3.6% (placebo 0%) sinus headache 3.6% (placebo 0%) NCT01086410 · Phase 3 · registry result, not featured evidence 100/25 µg PM headache 26.8% (placebo 8.6%) arthralgia 3.6% (placebo 0%) nasopharyngitis 3.6% (placebo 1.7%) NCT01086410 · Phase 3 · registry result, not featured evidence 100 µg AM headache 52.2% (placebo 36%) upper respiratory tract infection 26.1% (placebo 8%) nasopharyngitis 8.7% (placebo 4%) NCT01808339 · Phase 2 · registry result, not featured evidence 100 µg PM headache 41.7% (placebo 36%) viral upper respiratory tract infection 20.8% (placebo 8%) dysmenorrhoea 8.3% (placebo 8%) NCT01808339 · Phase 2 · registry result, not featured evidence 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 100 µg headache 11.5% (placebo 0%) acute tonsillitis 3.8% (placebo 0%) cough 3.8% (placebo 0%) NCT01332292 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence 200 µg OD upper respiratory tract infection 5% (placebo 1.1%) NCT00766090 · Phase 2 · registry result, not featured evidence 100 µg BID upper respiratory tract infection 4.9% (placebo 1.1%) NCT00766090 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
- bPopulation comparability has not been reviewed for 41 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
albuterol / budesonide
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 12 further endpoints in the CSV export.
Fluticasone Furoate
show 3 more results
show 20 more results
show 22 more results
show 16 more results
show 17 more results
show 4 more results
show 5 more results
show 2 more results
+ 30 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Fluticasone Furoate's landscape